Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P49821

UPID:
NDUV1_HUMAN

ALTERNATIVE NAMES:
Complex I-51kD; NADH dehydrogenase flavoprotein 1; NADH-ubiquinone oxidoreductase 51 kDa subunit

ALTERNATIVE UPACC:
P49821; O60924; O60940; Q16104; Q6IBR3; Q96BF8; Q96HS7

BACKGROUND:
The protein NADH dehydrogenase [ubiquinone] flavoprotein 1, located in mitochondria, is essential for the respiratory chain's electron transport, acting as a bridge in the transfer of electrons from NADH to ubiquinone. Known alternatively as NADH-ubiquinone oxidoreductase 51 kDa subunit, its function is vital for oxidative phosphorylation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of NADH dehydrogenase [ubiquinone] flavoprotein 1 could open doors to potential therapeutic strategies for treating a range of mitochondrial disorders, including Leigh syndrome and Parkinson disease, by correcting the underlying mitochondrial dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.